Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ITRAQ analysis of immortalized mouse Schwann cells treated with Ixazomib

ABSTRACT: To determine differentially expressed proteins upon treatment with proteasome inhibitor, Ixazomib, in cultured mouse Schwann cells

ORGANISM(S): Mus Musculus (mouse)

SUBMITTER: Kazunori Sango

PROVIDER: PXD036003 | JPOST Repository | Sat Sep 24 00:00:00 BST 2022

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Similar Datasets

RNA seq of HGPS treated cells

Project description:Evaluation of transcript levels in HGPS cells upon treatment with proteasome inhibitor

2017-06-18 | E-MTAB-5807 | biostudies-arrayexpress

Homo sapiens

Project description:Identification differentially expressed genes upon valproic acid treatment

| PRJNA143291 | ENA

Proteomic analysis to identify altered proteins asoociated with different molecular pathways from livers of mice treated with ibuprofen

Project description:Ibuprofen, an inhibitor of prostanoid biosynthesis is the most common pharmacological agent used for the management of pain, inflammation and fever. However, the chronic use of ibuprofen at high doses is associated with increased risk for cardiovascular, renal, gastrointestinal and liver injuries. The underlying mechanisms of ibuprofen-mediated effects on mice liver and proteasome function remain unclear. To determine the mechanisms and pathways affected by ibuprofen treatment (100mg/kg for 7 days), we performed proteomic profiling of male mice liver with quantitative LC-MS/MS using ten-plex tandem mass tag (TMT) labeling. More than 300 proteins were significantly altered between the control and ibuprofen-treated groups. Independent validation of proteomic data by Western blotting was carried out on 14 proteins using both male and female samples. Additional proteasome and immunoproteasome activity/expression was assayed to evaluate differences in proteasome function between male and female mice liver. Our data suggests that these differentially expressed proteins were found to be associated with several major pathways including (1) energy metabolism, (2) protein degradation, (3) fatty acid synthesis and (4) anti-oxidant system. The study suggests that the sex-related differences in the energy metabolism and proteasome dysfunction are underlying mechanisms for ibuprofen-mediated effects in mice liver and provide insights on novel molecular targets for future drug discovery and development.

2019-06-17 | MSV000083987 | MassIVE

Transcriptional regulation in MCF-7 breast cancer cells treated with proteasome inhibitor MG132 [rna_polii_chIP-seq]

Project description:We report whole genome chromatin immunoprecipitation followed by sequencing (ChIP-seq) of 3 different RNA Pol II CTD modifications in MCF-7 breast cancer cells treated with vehicle (UNTR) or the proteasome inhibitor MG132 for 4 (MG4H) or 24 (MG24H) hours. We find the non-phosphorylated form of RNA Pol II CTD accumulates at TSS of all expressed genes in proteasome inhibited cells, particularly after 24H of MG132 treatment. Proteasome inhibition enhances Ser5-P and Ser2-P binding at TSS of genes induced by MG132. We note that proteasome inhibition establishes unique Ser2-P 5’ to 3’ gene profiles at induced compared to repressed genes. Overall proteasome inhibition enhances RNA Pol II processivity and expression of gene networks relevant to breast cancer. The study provides a comprehensive resource of RNA Pol II binding in proteasome inhibited cells.

2020-01-07 | GSE142010 | GEO

Homo sapiens

Project description:Genes differentially expressed upon CHD8 knockdown

| PRJNA106441 | ENA

Expression data from lung SCC treated with DMSO and PXD101

Project description:We used microarrays to detail the global programme of gene expression in lung SCC cells treated with belinostat, a pan-HDAC inhibitor. The primary focus of this work is to investigate the efficacy of belinostat on lung SCC cells. Our phosphoproteomic profiling analyses revealed the downregulation of MAPK signaling pathway upon drug treatment, together with the induction of apoptosis. While HDAC inhibition generally affects transcription, the mechanism of SOS/MAPK downregulation was therefore proposed to be affected at the transcriptomic level. However, genes related to MAPK pathway were not significantly regulated upon belinostat treatment, whereas ubiquitin-proteasome gene signature was affected. This supports an indirect mechanism of epigenetic regulation on MAPK signaling that should be explored further.

2017-08-31 | GSE85979 | GEO

Expression data from MCF7 cells treated with hits from screening cytotoxic michael acceptors

Project description:We used a chemical library to screen for cytotoxic compounds with Michael acceptor groups that induce a cellular response characteristic of proteasome inhibition. We then determined the differentially expressed genes in MCF7 cells following treatment with each of the identified hits This dataset includes expression data from MCF7 cells treated with either DMSO or one of the treatment compounds

2022-02-17 | GSE193542 | GEO

Homo sapiens

Project description:Identification of differentially expressed genes upon treatment with Eltrombopag in HL60 cells

| PRJNA161883 | ENA

Expression data from ependymal cell cultures treated with MLN4924.

Project description:We identified that Foxj1 is degraded by the ubiquitin proteasome system. Foxj1 protein is stabilized by the cullin-RING ligase inhibitor MLN4924. We evaluated global changes to ependymal cell culture gene expression profiles during MLN4924 treatment.

2018-02-28 | GSE111182 | GEO

Gene expression data from MCF-7 cells treated with Lacciac Acid A

Project description:Lacciac Acid A was indentified as an inhibitor of DMNT1. MCF-7 cells were treated with Lacciac Acid A (200 uM) for 5 days. Changes in gene expression were identified by using Affymetrix Human gene ST1.0 arrays. We used microarrays to determine global changes in gene expression upon treatment with Lacciac Acid A an inhibitor of DMNT1.

2013-09-03 | GSE45804 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data